Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MISTBullishCorporate Developmentsnews

High materiality7/10

China PSVT approval unlocks Milestone's Greater China growth catalyst

Sep 3, 2026, 9:48 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Immediate $2M milestone cash and potential up to $98M in milestones plus royalties create visible, near-term cash/valuation upside; China commercialization could unlock significant long-term revenue, though timing depends on Everest's rollout.

AI summary

What happened, with direct paths to the underlying reporting

Milestone Pharmaceuticals received NMPA approval for etripamil nasal spray (CARDAMYST) in adults with PSVT, triggering a $2.0M milestone payment. Everest Medicines will commercialize in Greater China under an exclusive license, with Milestone eligible for up to $98M in milestones and up to 18% royalties. Phase 3 data (JX02002) showed strong efficacy; the market opportunity in China could drive a meaningful uplift in value over the next 6–12 months.

NMPA approves etripamil nasal spray for PSVT in adults. Triggers $2.0M milestone to Milestone.
Everest Medicines to lead commercialization in Greater China under exclusive license. Milestone license with Milestone to develop etripamil there.
JX02002 Phase 3 met primary endpoint; HR 3.002; p=0.0005. Safety events comparable; no serious AEs within 24 hours.
China PSVT market estimated 3-6M patients; US ~2M. Potential revenue ramp from Greater China license.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.